Hereditary diffuse gastric adenocarcinoma

Summary

Hereditary diffuse gastric adenocarcinoma (MONDO:0007648) is a disease caused by CDH1 (GenCC Definitive), with 6 cohort genes and 5 clinical trials.

At a glance

• Prevalence: Unknown (Worldwide)
• Causal gene: CDH1 (GenCC Definitive)
• Cohort genes: 6
• ClinVar variants: 4,701
• Clinical trials: 5

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	1.5	Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	hereditary diffuse gastric adenocarcinoma
Mondo ID	MONDO:0007648
Orphanet	26106
DOID	DOID:0080764
NCIT	C43295
SNOMED CT	716859000
UMLS	C1708349
MedGen	310839
GARD	0010900
Is cancer (heuristic)	no

Also known as: diffuse gastric cancer · familial diffuse cancer of stomach · familial diffuse gastric cancer · FDGC · HDGC · hereditary diffuse cancer of stomach · hereditary diffuse gastric adenocarcinoma · hereditary diffuse gastric cancer · signet cell adenocarcinoma · signet ring cell gastric carcinoma · signet ring gastric carcinoma

Data availability: 4,701 ClinVar variants · 2 ClinGen variant curations · 4 GenCC gene-disease records · 1 cell line.

Disease family

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastric cancer › gastric carcinoma › gastric adenocarcinoma › diffuse gastric adenocarcinoma › hereditary diffuse gastric adenocarcinoma

Related subtypes (1): gastric linitis plastica

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

600 retrieved; paginated sample, class counts are floors:

184 uncertain significance, 155 benign/likely benign, 122 likely benign, 54 conflicting classifications of pathogenicity, 46 pathogenic, 30 benign, 5 pathogenic/likely pathogenic, 4 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1066643	NM_004360.5(CDH1):c.1008+1G>T	CDH1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1068969	NM_004360.5(CDH1):c.1569T>G (p.Tyr523Ter)	CDH1	Pathogenic	criteria provided, multiple submitters, no conflicts
1069664	NC_000016.10:g.68829654del	CDH1	Pathogenic	criteria provided, single submitter
1069750	NM_004360.5(CDH1):c.1641del (p.Glu547fs)	CDH1	Pathogenic	criteria provided, single submitter
1069973	NM_004360.5(CDH1):c.1920dup (p.Gln641fs)	CDH1	Pathogenic	criteria provided, single submitter
1070687	NM_004360.5(CDH1):c.1616del (p.Thr539fs)	CDH1	Pathogenic	criteria provided, single submitter
1071176	NC_000016.9:g.(?68835563)(68863710_?)del	CDH1	Pathogenic	criteria provided, single submitter
1071177	NC_000016.9:g.(?68820946)(68842761_?)del	CDH1	Pathogenic	criteria provided, single submitter
1071833	NM_004360.5(CDH1):c.150_151dup (p.Val51fs)	CDH1	Pathogenic	criteria provided, single submitter
1072002	NM_004360.5(CDH1):c.1711+1dup	CDH1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1072150	NM_004360.5(CDH1):c.555del (p.Gly186fs)	CDH1	Pathogenic	criteria provided, multiple submitters, no conflicts
1072773	NM_004360.5(CDH1):c.1356_1362del (p.His453fs)	CDH1	Pathogenic	criteria provided, single submitter
1072979	NC_000016.9:g.(?68771319)(68835806_?)del	CDH1	Pathogenic	criteria provided, single submitter
1072980	NC_000016.9:g.(?_68857535)_68864666del	CDH1	Pathogenic	criteria provided, single submitter
1072981	NC_000016.9:g.(?68863547)(68867402_?)del	CDH1	Pathogenic	criteria provided, single submitter
1072982	NC_000016.9:g.(?68772190)(68849672_?)del	CDH1	Pathogenic	criteria provided, single submitter
1074240	NM_004360.5(CDH1):c.1695_1696insTT (p.Ile566fs)	CDH1	Pathogenic	criteria provided, single submitter
1074394	NM_004360.5(CDH1):c.1878_1885del (p.Phe626fs)	CDH1	Pathogenic	criteria provided, multiple submitters, no conflicts
1075278	NC_000016.10:g.68815516del	CDH1	Pathogenic	criteria provided, multiple submitters, no conflicts
1076986	NC_000016.9:g.(?68867183)(68867402_?)del	CDH1	Pathogenic	criteria provided, single submitter
1196343	NM_004360.5(CDH1):c.1577G>A (p.Trp526Ter)	CDH1	Pathogenic	criteria provided, multiple submitters, no conflicts
12234	NM_004360.5(CDH1):c.781G>T (p.Glu261Ter)	CDH1	Pathogenic	reviewed by expert panel
12237	NM_004360.5(CDH1):c.2095C>T (p.Gln699Ter)	CDH1	Pathogenic	reviewed by expert panel
12239	NM_004360.5(CDH1):c.59G>A (p.Trp20Ter)	CDH1	Pathogenic	reviewed by expert panel
12240	NM_004360.5(CDH1):c.70G>T (p.Glu24Ter)	CDH1	Pathogenic	reviewed by expert panel
12241	NM_004360.5(CDH1):c.1792C>T (p.Arg598Ter)	CDH1	Pathogenic	reviewed by expert panel
12244	NM_004360.5(CDH1):c.1901C>T (p.Ala634Val)	CDH1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
12251	NC_000016.10:g.68602418_68796011del	CDH1	Pathogenic	no assertion criteria provided
12252	NM_004360.5(CDH1):c.2440-396_*224delinsGGA	CDH1	Pathogenic	no assertion criteria provided
127915	NM_004360.5(CDH1):c.1565+1G>A	CDH1	Pathogenic	reviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 18 · Orphanet: 20 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
CDH1	Definitive	Autosomal dominant	hereditary diffuse gastric adenocarcinoma	15
MAP3K6	Supportive	Autosomal dominant	hereditary diffuse gastric adenocarcinoma	2
IL1B	No Known Disease Relationship	Unknown	hereditary diffuse gastric adenocarcinoma

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CDH1	Orphanet:1331	Familial prostate cancer
CDH1	Orphanet:199306	Cleft lip/palate
CDH1	Orphanet:1997	Blepharo-cheilo-odontic syndrome
CDH1	Orphanet:227535	Hereditary breast cancer
CDH1	Orphanet:26106	Hereditary diffuse gastric cancer
MAP3K6	Orphanet:26106	Hereditary diffuse gastric cancer
CTNNA1	Orphanet:26106	Hereditary diffuse gastric cancer
CTNNA1	Orphanet:99001	Butterfly-shaped pigment dystrophy
KRAS	Orphanet:1333	Familial pancreatic carcinoma
KRAS	Orphanet:1340	Cardiofaciocutaneous syndrome
KRAS	Orphanet:144	Lynch syndrome
KRAS	Orphanet:146	Differentiated thyroid carcinoma
KRAS	Orphanet:2396	Encephalocraniocutaneous lipomatosis
KRAS	Orphanet:251615	Pilomyxoid astrocytoma
KRAS	Orphanet:2612	Linear nevus sebaceus syndrome
KRAS	Orphanet:268114	RAS-associated autoimmune leukoproliferative disease
KRAS	Orphanet:3339	Oculoectodermal syndrome
KRAS	Orphanet:648	Noonan syndrome
KRAS	Orphanet:86834	Juvenile myelomonocytic leukemia
RAD54L	Orphanet:227535	Hereditary breast cancer

Cohort genes → proteins

6 cohort genes, 6 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	6

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CDH1	HGNC:1748	ENSG00000039068	P12830	Cadherin-1	gencc,clinvar
IL1B	HGNC:5992	ENSG00000125538	P01584	Interleukin-1 beta	gencc
MAP3K6	HGNC:6858	ENSG00000142733	O95382	Mitogen-activated protein kinase kinase kinase 6	gencc
CTNNA1	HGNC:2509	ENSG00000044115	P35221	Catenin alpha-1	clinvar
KRAS	HGNC:6407	ENSG00000133703	P01116	GTPase KRas	clinvar
RAD54L	HGNC:9826	ENSG00000085999	Q92698	DNA repair and recombination protein RAD54-like	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CDH1	Cadherin-1	Cadherins are calcium-dependent cell adhesion proteins.
IL1B	Interleukin-1 beta	Potent pro-inflammatory cytokine.
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	Component of a protein kinase signal transduction cascade.
CTNNA1	Catenin alpha-1	Associates with the cytoplasmic domain of a variety of cadherins.
KRAS	GTPase KRas	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
RAD54L	DNA repair and recombination protein RAD54-like	Multifunctional ATPase that plays a role in homologous recombination (HR) which is a major pathway for repairing DNA double-strand breaks (DSBs), single-stranded DNA (ssDNA) gaps, and stalled or collapsed replication forks.

Protein-family classification

Druggable: 3 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	2	4.0×	0.249
Kinase	1	4.6×	0.297
Other/Unknown	3	0.9×	0.758

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CDH1	Other/Unknown	no		Cadherin_Y-type_LIR, Cadherin-like_dom, Cadherin_pro_dom
IL1B	Other/Unknown	no		IL-1_fam, IL-1_propep, IL1/FGF
MAP3K6	Kinase	yes	2.7.11.25	Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
CTNNA1	Other/Unknown	no		Vinculin_CS, Alpha_catenin, Vinculin/catenin
KRAS	Enzyme (other)	yes	3.6.5.2	Small_GTPase, Small_GTP-bd, Small_GTPase_Ras-type
RAD54L	Enzyme (other)	yes	3.6.4.B9	SNF2_N, Helicase_C-like, Helicase_ATP-bd

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	6
unknown	0

Top tissues across cohort

Tissue	Cohort genes
esophagus squamous epithelium	1
gingival epithelium	1
jejunal mucosa	1
granulocyte	1
monocyte	1
periodontal ligament	1
lower esophagus mucosa	1
right lung	1
skin of abdomen	1
amniotic fluid	1
calcaneal tendon	1
colonic epithelium	1
nipple	1
pylorus	1
trigeminal ganglion	1
left testis	1
right testis	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CDH1	245	broad	marker	jejunal mucosa, esophagus squamous epithelium, gingival epithelium
IL1B	228	ubiquitous	marker	periodontal ligament, granulocyte, monocyte
MAP3K6	227	ubiquitous	marker	lower esophagus mucosa, right lung, skin of abdomen
CTNNA1	305	ubiquitous	marker	colonic epithelium, calcaneal tendon, amniotic fluid
KRAS	298	ubiquitous	marker	trigeminal ganglion, pylorus, nipple
RAD54L	173	ubiquitous	yes	left testis, right testis, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
KRAS	14,509
CDH1	8,738
IL1B	8,564
CTNNA1	3,128
RAD54L	2,927
MAP3K6	941

Intra-cohort edges

A	B	Sources
CDH1	CTNNA1	intact, string_interaction
CTNNA1	MAP3K6	string_interaction

Structural data

PDB: 5 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
KRAS	P01116	511
IL1B	P01584	64
CDH1	P12830	22
CTNNA1	P35221	10
RAD54L	Q92698	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
MAP3K6	O95382	75.36

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 129. Enrichment computed across 6 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Regulation of CDH1 Function	2	475.8×	8e-04	CDH1, CTNNA1
SRC activates STAT3 in a quantitative manner, through Cadherin-11 (CDH11), RAC1 and gp130 (IL6ST)	2	248.3×	0.001	CDH1, CTNNA1
RHO GTPases activate IQGAPs	2	173.0×	0.002	CDH1, CTNNA1
Adherens junctions interactions	2	124.1×	0.003	CDH1, CTNNA1
Degradation of CDH1	2	98.5×	0.004	CDH1, CTNNA1
Activation of STAT3 by cadherin engagement	2	81.6×	0.005	CDH1, CTNNA1
Signaling by RAS GAP mutants	1	951.7×	0.015	KRAS
Signaling by RAS GTPase mutants	1	951.7×	0.015	KRAS
Activation of RAS in B cells	1	571.0×	0.015	KRAS
CASP4-mediated substrate cleavage	1	571.0×	0.015	IL1B
CASP5-mediated substrate cleavage	1	571.0×	0.015	IL1B
CLEC7A/inflammasome pathway	1	475.8×	0.015	IL1B
RAS signaling downstream of NF1 loss-of-function variants	1	407.9×	0.015	KRAS
Estrogen-stimulated signaling through PRKCZ	1	407.9×	0.015	KRAS
CDH11 homotypic and heterotypic interactions	1	407.9×	0.015	CTNNA1
SOS-mediated signalling	1	356.9×	0.015	KRAS
Epithelial-Mesenchymal Transition (EMT) during gastrulation	1	356.9×	0.015	CDH1
Regulation of CDH19 Expression and Function	1	356.9×	0.015	CTNNA1
Interleukin-1 processing	1	317.2×	0.015	IL1B
InlA-mediated entry of Listeria monocytogenes into host cells	1	317.2×	0.015	CDH1
Activated NTRK3 signals through RAS	1	317.2×	0.015	KRAS
EGFR Transactivation by Gastrin	1	285.5×	0.015	KRAS
SHC-related events triggered by IGF1R	1	285.5×	0.015	KRAS
RUNX3 regulates p14-ARF	1	285.5×	0.015	KRAS
Activated NTRK2 signals through RAS	1	285.5×	0.015	KRAS
Apoptotic cleavage of cell adhesion proteins	1	259.6×	0.015	CDH1
MET activates RAS signaling	1	259.6×	0.015	KRAS
Listeria monocytogenes entry into host cells	1	259.6×	0.015	CDH1
Regulation of CDH11 function	1	259.6×	0.015	CTNNA1
Regulation of CDH1 mRNA translation by microRNAs	1	259.6×	0.015	CDH1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cellular response to indole-3-methanol	2	1123.5×	2e-04	CDH1, CTNNA1
positive regulation of glial cell proliferation	2	234.1×	0.003	IL1B, KRAS
extrinsic apoptotic signaling pathway in absence of ligand	2	156.0×	0.004	CTNNA1, IL1B
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	2	137.0×	0.004	CTNNA1, IL1B
JNK cascade	2	90.6×	0.007	IL1B, MAP3K6
response to mineralocorticoid	1	2808.7×	0.009	KRAS
positive regulation of cell adhesion molecule production	1	2808.7×	0.009	IL1B
positive regulation of T cell mediated immunity	1	1404.3×	0.010	IL1B
positive regulation of complement activation	1	1404.3×	0.010	IL1B
regulation of nitric-oxide synthase activity	1	1404.3×	0.010	IL1B
positive regulation of RNA biosynthetic process	1	1404.3×	0.010	IL1B
negative regulation of gap junction assembly	1	1404.3×	0.010	IL1B
fever generation	1	936.2×	0.010	IL1B
forebrain astrocyte development	1	936.2×	0.010	KRAS
monocyte aggregation	1	936.2×	0.010	IL1B
response to heparin	1	936.2×	0.010	CDH1
smooth muscle adaptation	1	702.2×	0.010	IL1B
positive regulation of fever generation	1	702.2×	0.010	IL1B
response to isolation stress	1	702.2×	0.010	KRAS
double-strand break repair via synthesis-dependent strand annealing	1	702.2×	0.010	RAD54L
negative regulation of adiponectin secretion	1	702.2×	0.010	IL1B
regulation of protein catabolic process at postsynapse, modulating synaptic transmission	1	702.2×	0.010	CDH1
negative regulation of integrin-mediated signaling pathway	1	702.2×	0.010	CTNNA1
cytokine-mediated signaling pathway	2	43.5×	0.010	IL1B, KRAS
cell-cell adhesion	2	33.8×	0.010	CDH1, CTNNA1
positive regulation of platelet-derived growth factor receptor signaling pathway	1	561.7×	0.010	IL1B
negative regulation of D-glucose transmembrane transport	1	561.7×	0.010	IL1B
hyaluronan biosynthetic process	1	561.7×	0.010	IL1B
negative regulation of lipid metabolic process	1	561.7×	0.010	IL1B
positive regulation of tight junction disassembly	1	561.7×	0.010	IL1B

Therapeutics

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 4 · Undrugged: 2

Druggability breadth: 6 of 6 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
IL1B	POMALIDOMIDE
MAP3K6	LENVATINIB
KRAS	VEMURAFENIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
KRAS	11	4
MAP3K6	6	4
IL1B	4	4
RAD54L	1	2
CDH1	0	0
CTNNA1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
POMALIDOMIDE	4	IL1B
LENALIDOMIDE	4	IL1B
LENVATINIB	4	MAP3K6
VEMURAFENIB	4	KRAS
DABRAFENIB	4	KRAS
LONAFARNIB	4	KRAS
SOTORASIB	4	KRAS
ADAGRASIB	4	KRAS
IBERDOMIDE	3	IL1B
SELONSERTIB	3	MAP3K6
LESTAURTINIB	3	MAP3K6
OPNURASIB	3	KRAS
AVADOMIDE	2	IL1B
UCN-01	2	MAP3K6
DIVARASIB	2	KRAS
GLECIRASIB	2	KRAS
STREPTONIGRIN	2	RAD54L
PF-03814735	1	MAP3K6
AST-487	1	MAP3K6
BMS-214662	1	KRAS
LY-3009120	1	KRAS
MRTX-1133	1	KRAS

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
KRAS	861	Binding:829, Functional:32
MAP3K6	103	Binding:103
IL1B	26	Binding:26
CDH1	18	Binding:18
RAD54L	3	Functional:2, Binding:1
CTNNA1	2	Binding:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
MAP3K6	2.7.11.25	mitogen-activated protein kinase kinase kinase
KRAS	3.6.5.2	small monomeric GTPase
RAD54L	3.6.4.B9

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
MAP3K6	103
KRAS	861

Pharmacogenomics

Cohort genes with a PharmGKB record: 6; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

22 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
POMALIDOMIDE	4	IL1B
LENALIDOMIDE	4	IL1B
LENVATINIB	4	MAP3K6
VEMURAFENIB	4	KRAS
DABRAFENIB	4	KRAS
LONAFARNIB	4	KRAS
SOTORASIB	4	KRAS
ADAGRASIB	4	KRAS
IBERDOMIDE	3	IL1B
SELONSERTIB	3	MAP3K6
LESTAURTINIB	3	MAP3K6
OPNURASIB	3	KRAS
AVADOMIDE	2	IL1B
UCN-01	2	MAP3K6
DIVARASIB	2	KRAS
GLECIRASIB	2	KRAS
STREPTONIGRIN	2	RAD54L
PF-03814735	1	MAP3K6
AST-487	1	MAP3K6
BMS-214662	1	KRAS
LY-3009120	1	KRAS
MRTX-1133	1	KRAS

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	IL1B, MAP3K6, KRAS
B	Phased (≥1) drug, not yet approved	1	RAD54L
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	CDH1, CTNNA1

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CDH1	18	—
CTNNA1	2	—

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00633607	Not specified	COMPLETED	Hereditary Colorectal and Associated Tumor Registry Study
NCT03030404	Not specified	COMPLETED	Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
NCT03950908	Not specified	COMPLETED	Biopsy Technique for Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer
NCT04253106	Not specified	COMPLETED	Liquid Biopsies for the Personalized Management of Patients with Hereditary Diffuse Gastric Cancer
NCT06163365	Not specified	UNKNOWN	Inherited Cancer Early Diagnosis (ICED) Study